Evogene (EVGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.70M
Last updated: Nov 17, 2026 at 11:05 AM ET
Evogene (EVGN) Competitors
The companies most similar to Evogene are Soligenix (SNGX), GT Biopharma (GTBP) and In8bio (INAB). By market cap, Evogene ranks 10th of the 13 companies on this page; Vyome Holdings (HIND) is the largest at $11.09M.
Peer Comparison
EVGN's revenue growth of -60.7% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Evogene (EVGN) | $6.70M | N/A | 3.7x | 0.0% | N/A | -60.7% | 0.00% |
| Soligenix Inc. (SNGX) | $7.50M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| In8bio Inc (INAB) | $8.86M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Senti Biosciences Inc (SNTI) | $5.38M | N/A | 57.2x | 0.0% | 1039.8% | -100.0% | 0.00% |
| Ensysce Biosciences Inc (ENSC) | $8.14M | N/A | 1.2x | -280.5% | -260.6% | -15.1% | 0.00% |
| VistaGen Therapeutics Inc (VTGN) | $8.01M | N/A | 3.4x | 0.0% | N/A | -46.5% | 0.00% |
| Exicure Inc (XCUR) | $7.07M | N/A | N/A | 0.0% | N/A | 928.0% | 0.00% |
| Vyome Holdings, Inc. (HIND) | $11.09M | N/A | N/A | 0.0% | N/A | 67.5% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Galmed Pharmaceuticals Ltd (GLMD) | $4.95M | N/A | N/A | 0.0% | N/A | 0.0% | N/A |
| Longeveron LLC (LGVN) | $8.40M | N/A | 5.9x | 0.0% | N/A | -9.2% | 0.00% |
| Peer median | $7.84M | N/A | 5.9x | 0.0% | -52.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Evogene, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Soligenix Inc. (SNGX) | Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. | SNGX competitors |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| In8bio Inc (INAB) | IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers... | INAB competitors |
| Senti Biosciences Inc (SNTI) | Senti Biosciences Inc (SNTI) is a leading biotechnology firm specializing in synthetic biology... | SNTI competitors |
| Ensysce Biosciences Inc (ENSC) | Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. | ENSC competitors |
| VistaGen Therapeutics Inc (VTGN) | VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential... | VTGN competitors |
| Exicure Inc (XCUR) | Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases... | XCUR competitors |
| Vyome Holdings, Inc. (HIND) | Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States... | HIND competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| Galmed Pharmaceuticals Ltd (GLMD) | Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment of liver diseases. | |
| Longeveron LLC (LGVN) | Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions. | LGVN competitors |
Frequently Asked Questions About EVGN
Who are Evogene's main competitors?
The companies most similar to Evogene include Soligenix (SNGX), GT Biopharma (GTBP), In8bio (INAB), Senti Biosciences (SNTI) and Ensysce Biosciences (ENSC), listed from the closest match.
Who is Evogene's biggest competitor?
Vyome Holdings (HIND) is the largest of the similar companies at $11.09M; Soligenix (SNGX) is the closest match by business profile, size, sector and industry.
How does EVGN stock compare with its competitors?
EVGN's P/S is 3.7x against a peer median of 5.9x; its net margin is 0.0% against a peer median of 0.0%.
Which of Evogene's competitors pays a higher dividend?
Evogene pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Evogene bigger than its competitors?
No. Evogene is 10th by market cap among the 13 companies on this page; the largest is Vyome Holdings (HIND) at $11.09M.
EVGN pages: Overview, Earnings, Forecast, Financials, Competitors